Search Results - "Broad, Robyn"

Inhibition of interferon-signalling halts cancer-associated fibroblast-dependent protection of breast cancer cells from chemotherapy by Broad, Robyn V., Jones, Stacey J., Teske, Melina C., Wastall, Laura M., Hanby, Andrew M., Thorne, James L., Hughes, Thomas A.

“…Background Triple negative breast cancers (TNBC) have poor prognoses despite aggressive treatment with cytotoxic chemotherapy. Cancer-associated fibroblasts…”
Get full text

Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer by Blumenschein, George R, Devarakonda, Siddhartha, Johnson, Melissa, Moreno, Victor, Gainor, Justin, Edelman, Martin J, Heymach, John V, Govindan, Ramaswamy, Bachier, Carlos, Doger de Spéville, Bernard, Frigault, Matthew J, Olszanski, Anthony J, Lam, Vincent K, Hyland, Natalie, Navenot, Jean-Marc, Fayngerts, Svetlana, Wolchinsky, Zohar, Broad, Robyn, Batrakou, Dzmitry, Pentony, Melissa M, Sanderson, Joseph P, Gerry, Andrew, Marks, Diane, Bai, Jane, Holdich, Tom, Norry, Elliot, Fracasso, Paula M

“…BackgroundADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T cells (ADP-A2M10) are genetically engineered autologous T cells that express a…”
Get full text

Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors by Hong, David S, Butler, Marcus O, Pachynski, Russell K, Sullivan, Ryan, Kebriaei, Partow, Boross-Harmer, Sarah, Ghobadi, Armin, Frigault, Matthew J, Dumbrava, Ecaterina E, Sauer, Amy, Brophy, Francine, Navenot, Jean-Marc, Fayngerts, Svetlana, Wolchinsky, Zohar, Broad, Robyn, Batrakou, Dzmitry G, Wang, Ruoxi, Solis, Luisa M, Duose, Dzifa Yawa, Sanderson, Joseph P, Gerry, Andrew B, Marks, Diane, Bai, Jane, Norry, Elliot, Fracasso, Paula M

“…ADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T-cells are genetically engineered autologous T-cells that express a high-affinity…”
Get full text

Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients by Wang, Tianjiao, Navenot, Jean-Marc, Rafail, Stavros, Kurtis, Cynthia, Carroll, Mark, Van Kerckhoven, Marian, Van Rossom, Sofie, Schats, Kelly, Avraam, Konstantinos, Broad, Robyn, Howe, Karen, Liddle, Ashley, Clayton, Amber, Wang, Ruoxi, Quinn, Laura, Sanderson, Joseph P., McAlpine, Cheryl, Carozza, Carly, Pimpinella, Eric, Hsu, Susan, Brophy, Francine, Elefant, Erica, Bayer, Paige, Williams, Dennis, Butler, Marcus O., Clarke, Jeffrey M., Gainor, Justin F., Govindan, Ramaswamy, Moreno, Victor, Johnson, Melissa, Tu, Janet, Hong, David S., Blumenschein, George R.

“…T cell receptor (TCR) T cell therapies target tumor antigens in a human leukocyte antigen (HLA)-restricted manner. Biomarker-defined therapies require…”
Get full text

376 Radiation sub-study to characterize safety and tolerability of low-dose radiation in combination with afami-cel in patients with advanced cancers (NCT03132922) by Welsh, James, Ke, Danxia, Osorio, Nahum Puebla, Barsoumian, Hampartsoum, Jackson, Bryan, Bai, Jane, Rosenberg, Marisa, McAlpine, Cheryl, Broad, Robyn, Liddle, Ashley, Navenot, Jean-Marc, Rafail, Stavros, Wang, Ruoxi, Sauer, Amy, Lin, Quan, Danesi, Hassan, Hong, David

“…BackgroundAutologous cell therapies with an engineered T-cell receptor targeting MAGE-A4 have shown responses in patients with synovial sarcoma1 with…”
Get full text

Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A02+ patients: a phase 1 trial by Hong, David S., Van Tine, Brian A., Biswas, Swethajit, McAlpine, Cheryl, Johnson, Melissa L., Olszanski, Anthony J., Clarke, Jeffrey M., Araujo, Dejka, Blumenschein, George R., Kebriaei, Partow, Lin, Quan, Tipping, Alex J., Sanderson, Joseph P., Wang, Ruoxi, Trivedi, Trupti, Annareddy, Thejo, Bai, Jane, Rafail, Stavros, Sun, Amy, Fernandes, Lilliam, Navenot, Jean-Marc, Bushman, Frederic D., Everett, John K., Karadeniz, Derin, Broad, Robyn, Isabelle, Martin, Naidoo, Revashnee, Bath, Natalie, Betts, Gareth, Wolchinsky, Zohar, Batrakou, Dzmitry G., Van Winkle, Erin, Elefant, Erica, Ghobadi, Armin, Cashen, Amanda, Grand’Maison, Anne, McCarthy, Philip, Fracasso, Paula M., Norry, Elliot, Williams, Dennis, Druta, Mihaela, Liebner, David A., Odunsi, Kunle, Butler, Marcus O.

“…Affinity-optimized T cell receptors can enhance the potency of adoptive T cell therapy. Afamitresgene autoleucel (afami-cel) is a human leukocyte…”
Get full text

Preliminary clinical outcomes of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced urothelial cancer by Aggen, David H, Hong, David S., Clarke, Jeffrey Melson, Asch, Adam Steven, Calvo, Emiliano, Zugazagoitia, Jon, Butler, Marcus O., Moreno, Victor, Cervantes, Andres, Van Tine, Brian Andrew, Lawrence, Donald P., Johnson, Melissa Lynne, Brophy, Francine Elizabeth, Broad, Robyn, Isabelle, Martin, Gunn, Alasdair, Navenot, Jean-Marc, Saro, Jose, Norry, Elliot, Charlson, John A.

“…517 Background: ADP-A2M4CD8 is a specific peptide enhanced affinity receptor mixed CD4+ and CD8+ T-cell therapy targeting the cancer testis antigen MAGE-A4 and…”
Get full text

Abstract 892: Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4) demonstrates durable clinical responses by inducing broad immune engagement with anti-tumor activity by McAlpine, Cheryl, Isabelle, Martin, Broad, Robyn, Naidoo, Revashnee, Liddle, Ashley, Duperret, Elizabeth, Noto, Paul, Wang, Ruoxi, Batrakou, Dzmitry, Middha, Sumit, Evans, Chris

“…Abstract Afami-cel is a mixed CD4+ CD8+ autologous T-cell therapy engineered to target the cancer testis antigen melanoma-associated antigen A4 in…”
Get full text

The role of fibroblasts in chemoresistance in triple negative breast cancer by Broad, Robyn Victoria

Get full text